Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). “There have been limited […]Continue Reading ...
August 14, 2018 The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold. A team led by Dr Vadim Sumbayev, of the University’s Medway School of Pharmacy, found for the first time that blood/bone marrow cancer […]Continue Reading ...
July 20, 2018 AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for venetoclax in combination with a hypomethylating agent (HMA) or in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed patients with acute myeloid leukemia (AML) […]Continue Reading ...
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: VashiDonsk/Wikipedia/CC BY-SA 3.0 Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukaemia (AML) years before diagnosis. The researchers from Wellcome Sanger Institute, European Bioinformatics Institute (EMBL-EBI) and their international collaborators found that patients […]Continue Reading ...
July 10, 2018 An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer. The findings, published today in Nature, illuminate the ‘black box of leukemia’ and answer the question of where, when and how the disease begins, […]Continue Reading ...
April 24, 2018 Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that comprises 1% of all new cancer cases and almost 2% of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20%. Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at […]Continue Reading ...
ivosidenib Treatment for Acute Myeloid Leukemia FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced […]Continue Reading ...
September 1, 2017 Pfizer Inc. nowadays introduced that the U.S. Meals and Drug Management licensed MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly identified CD33-positive acute myeloid leukemia (AML), and adults and kids 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG is the primary remedy with a sign that incorporates pediatric AML. It […]Continue Reading ...
July 20, 2018 The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used […]Continue Reading ...
July 17, 2018 For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about […]Continue Reading ...
By Sally Robertson, BScJuly 11, 2018 Researchers from Cincinnati Children’s Hospital have made important discoveries about the molecular mechanisms driving acute myeloid leukemia (AML), a deadly pediatric cancer. The findings could lead to the development of new treatments. MLL-AF9 Leukemia Cells. (Image Credit: Cincinnati Children’s) Writing in the Journal of Experimental Medicine, the scientists refer […]Continue Reading ...
May 18, 2018 Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes […]Continue Reading ...
April 11, 2018 In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II […]Continue Reading ...
FRIDAY, Sept. 1, 2017 (HealthDay Information) — The U.S. Meals and Drug Management on Friday licensed an altered dose of the drug Mylotarg to regard a particular form of acute myeloid leukemia — CD33-positive AML. An previous model of the drug were withdrawn from the marketplace when well being dangers began to emerge. Identified generically […]Continue Reading ...
September 1, 2017 The U.S. Meals and Drug Management lately authorized Mylotarg (gemtuzumab ozogamicin) for the remedy of adults with newly recognized acute myeloid leukemia whose tumors categorical the CD33 antigen (CD33-positive AML). The FDA additionally authorized Mylotarg for the remedy of sufferers elderly 2 years and older with CD33-positive AML who’ve skilled a relapse […]Continue Reading ...
- Adverse Childhood Experiences Tied to Burnout in BSN Students
- High levels of oral disease among elite athletes affecting performance
- Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
- LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
- Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
- Organic food may protect against cancers finds study
- Interweaving anxiety disorder associated with stuttering remains unrecognized
- Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
- Common antibodies associated with myocardial infarction
- Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
- Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
- Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
- Can virtual reality help people become more compassionate?
- Screen time eclipsed outdoor time for most students, shows study
- SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
- Plastics now commonly found in human stools
- Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
- Cancer survivors at risk for heart failure during, after pregnancy
- Stanford project brings health education videos to mothers in South Africa
- HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study